Sdp Japan
7 known investors
SDP Japan (Super Doctor Produce) supports the launch and operation of surgery-specialized hospitals and clinics, acting as a producer that connects doctors, patients, and healthcare institutions. It builds systems that let surgeons focus on their specialties while helping patients reach appropriate care, operating in Japan's healthcare sector.
Also known as SDP Japan Co., Ltd. · SDP JAPAN Inc. · SDP Japan, Inc. · SDPジャパン株式会社
Investors · 7
Also in the syndicate · 4
Company profile
researched Aug 2026SDP Japan, Inc. (SDPジャパン株式会社) is a Tokyo-based healthcare company that supports the launch and operation of surgery-specialized hospitals and clinics, positioning itself as a "Super Doctor Produce" platform for the surgical care sector. Its focus areas are orthopedics (joint and spine disease, including hip and knee replacement) and cardiovascular medicine (arrhythmia treatment). The company provides partner medical institutions with patient acquisition and marketing, supply and medical materials procurement, real estate and medical equipment sourcing, land and building leasing, management and back-office services, and administrative support.
Engagements are structured in two models described on the company's site: "total produce," in which SDP Japan supports the opening and running of a dedicated facility, and "selective produce," in which it supports a specialized department such as a joint replacement center inside an existing hospital. Supported institutions include Tokyo Heart Rhythm Clinic (Setagaya, Haneda, Shinjuku and Niigata locations), Setagaya Artificial Joint and Spine Clinic, Yokohama Machida Joint Spine Hospital, Tokyo Spine and Joint Clinic Haneda, Tokyo Hip Joint Clinic, Chiba Shirai Hospital, Tokorozawa Hakushokai Hospital and Shakai Hoken Omuta Tenryo Hospital.
The company states a mission of delivering inspiration and joy through advanced surgical care and a vision of becoming the leading surgical platform operator in Japan. It also aims to help establish a Japanese equivalent of the ambulatory surgical center (ASC) model adapted to the country's public insurance system.
Business model
SDP Japan operates as a business-to-business producer and operating partner for medical institutions rather than as a direct provider of care. It supplies partner hospitals and clinics with facility production, patient marketing, joint purchasing of surgical materials and medical consumables, leasing of land, buildings and medical equipment, and management and back-office outsourcing.
Revenue is associated with services provided to partner medical institutions, including management and back-office contracting, leasing of hospital land and buildings and medical equipment, and centralized procurement arrangements.
Traction
In 2024, facilities supported by SDP Japan performed over 3,000 surgeries, bringing the cumulative total to approximately 14,000. As of the June 2025 funding announcement the company had helped produce seven surgery-focused institutions in the Tokyo metropolitan area.
Latest developments
In June 2025 the company announced a Series D equity round led by Japan Post Investment alongside secondary transactions, debt and asset-based funding, totaling approximately JPY 4.5 billion (USD 31 million). It subsequently supported the opening of Tokyo Heart Rhythm Clinic Niigata (announced April 2026) and relaunched its corporate and recruiting website in February 2026.
▸Full profile — market position, go-to-market, geography, history
Market position
The company describes itself as a platform operator at the intersection of patient marketing, facility production and healthcare operations management in Japan's surgical care sector. Facilities it supports are reported to rank third in Tokyo for both arrhythmia procedures and hip joint replacement surgeries by procedure volume, citing Shukan Asahi Mook's "Best Hospitals for Surgery 2024."
SDP Japan combines patient acquisition, facility production and operations management in a single offering for surgery-focused institutions, allowing surgeons to concentrate on procedures while administrative, procurement, real estate and equipment functions are handled externally.
Go-to-market
The company partners directly with physicians and medical institutions to open new specialty facilities or to establish specialized surgical units inside existing hospitals, and drives patient volume to those facilities through marketing.
Surgeons and specialist physicians seeking to open or run surgery-focused clinics and hospitals, and hospitals establishing specialized surgical departments; patients seeking orthopedic and cardiovascular surgical treatment are reached through the supported institutions.
Geography
Operations are in Japan, with headquarters in Shibuya-ku, Tokyo (Dogenzaka). Supported institutions have been concentrated in the Tokyo metropolitan area, with announced expansion to Niigata, Chiba, Saitama and Fukuoka prefectures and a stated plan to extend its model to regional cities nationwide.
History
Company records list establishment in January 2014, while investor Globis Capital Partners lists a founding date of December 2013; the company's own release refers to its founding in 2014. Supported facilities opened beginning in 2016 with the Setagaya Artificial Joint and Spine Clinic and Tokyo Heart Rhythm Clinic Setagaya, followed by Tokyo Hip Joint Clinic (2019), Yokohama Machida Joint Spine Hospital (2020) and further openings in 2024 and 2025. Successive financings were reported in 2015, 2018, 2019, 2020 and 2025, and the company moved offices in 2023.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 18
launches, deals, and filingsSpecialized joint replacement department for knee and hip in Omuta, Fukuoka, under a selective produce engagement.
Inpatient clinic in Niigata City providing arrhythmia treatment and cardiac rehabilitation.
Specialized joint replacement department for knee and hip in Tokorozawa, Saitama, under a selective produce engagement.
Artificial joint center within the orthopedics department of a general hospital in Shirai, Chiba, under a selective produce engagement.
SDP Japan raised approximately JPY 4.5 billion (USD 31 million) through Series D equity financing alongside a secondary transaction, debt financing and asset-based funding. The equity round was led by Japan Post Investment with seven institutional investors participating; lenders included Resona Bank, Shizuoka Bank and SBI Shinsei Bank.
$31M source ↗
Outpatient-only clinic in Shibuya, Tokyo specializing in arrhythmia treatment.
Inpatient clinic in Ota, Tokyo specializing in arrhythmia treatment.
Inpatient clinic in Ota, Tokyo specializing in spine and joint disease treatment.
Hospital in Machida, Tokyo specializing in joint and spine disease treatment.
Outpatient clinic in Chiyoda, Tokyo specializing in hip joint replacement, under a selective produce engagement.
Inpatient clinic in Setagaya, Tokyo specializing in arrhythmia treatment.
Inpatient clinic in Setagaya, Tokyo specializing in joint and spine disease treatment, opened under a total produce engagement.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Sdp Japansdp-japan.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Sdp Japan do?
- SDP Japan produces and operates surgery-specialized hospitals and clinics in orthopedics and cardiovascular care in Japan.
- Who are Sdp Japan's investors?
- Sdp Japan's investors include Globis Capital Partners, Spiral Capital, Spiral Innovation Partners.